In June 2023, Merck announced the results of a Phase IIa clinical trial of efinopegdutide for the treatment of NASH
As the market evolves, healthcare professionals will play a central role in helping patients understand their treatment options while maintaining safe and evidence-based care
Apotex received tentative approval in April 2026, but Novo Nordisk's patents prevent it from launching until at least December 2031
So, it's very important to know the side effects, to understand the risks versus the benefits
[11] This form angular cheilitis which is caused by Candida is sometimes termed "Candida-associated angular cheilitis", [11] or less commonly, "monilial perlche"
However, weight loss results are generally modest, averaging 510 pounds over several months